Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
暂无分享,去创建一个
Jianmin Wu | Sean M. Grimmond | Christian Pilarsky | Carrie A. Davis | Daniela Aust | Darjus F. Tschaharganeh | Andrew V. Biankin | Scott W. Lowe | Carol Prives | S. Lowe | D. Aust | C. Pilarsky | A. Biankin | S. Grimmond | E. Markert | C. Davis | S. Moon | C. Prives | Jianmin Wu | E. Manchado | M. Saborowski | Thomas Kitzing | Susann Weissmueller | John P. Morris | Eusebio Manchado | Elvin Wagenblast | Sung-Hwan Moon | Michael Saborowski | Neil T. Pfister | Elke K. Markert | Elvin Wagenblast | T. Kitzing | N. Pfister | Susann Weissmueller | Eusebio Manchado | Carrie A. Davis
[1] Thierry Soussi,et al. Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.
[2] Jochen Gaedcke,et al. DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma , 2012, PloS one.
[3] J. Richardson,et al. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. , 2003, Blood.
[4] C. Verbeke,et al. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing , 2013, BMC Cancer.
[5] Carol Prives,et al. Mutant p53: one name, many proteins. , 2012, Genes & development.
[6] R. Hruban,et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.
[7] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[8] A. Levine,et al. The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.
[9] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[10] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[11] C. Prives,et al. A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. , 2009, Genes & Development.
[12] H. Nakshatri,et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion , 2007, Oncogene.
[13] W. B. Derry. Faculty Opinions recommendation of A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. , 2009 .
[14] U. Moll,et al. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis , 2013, Cell Death and Differentiation.
[15] P. Dong,et al. Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis , 2012, Oncogene.
[16] A. Hinke,et al. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205 , 2013, British Journal of Cancer.
[17] M. Hediger,et al. Mammalian iron transporters: families SLC11 and SLC40. , 2013, Molecular aspects of medicine.
[18] J. Norman,et al. Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.
[19] J. Pietenpol,et al. Targeting mutant p53 in human tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] C. Bracken,et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155 , 2013, Oncogene.
[21] Tobias Sjöblom,et al. PDGF receptors as cancer drug targets. , 2003, Cancer cell.
[22] T. Borodina,et al. Transcriptome analysis by strand-specific sequencing of complementary DNA , 2009, Nucleic acids research.
[23] Patrick J. Paddison,et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo , 2003, Nature Genetics.
[24] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[25] R. Mantovani,et al. Conservation and divergence of NF-Y transcriptional activation function. , 1998, Nucleic acids research.
[26] F. Holstege,et al. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. , 2013, Neoplasia.
[27] Toshio Ohhashi,et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. , 2004, Cancer cell.
[28] Shiyun Ling,et al. TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73 , 2011, Molecular and Cellular Biology.
[29] T. Yeatman,et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. , 2010, Gastroenterology.
[30] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[31] K. Funa,et al. Isolation and Characterization of the Mouse PDGF β-Receptor Promoter , 1995 .
[32] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[33] C. Prives,et al. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? , 2007, Oncogene.
[34] S. Offermanns,et al. Gα12/13 Is Essential for Directed Cell Migration and Localized Rho-Dia1 Function* , 2005, Journal of Biological Chemistry.
[35] P. Sismondi,et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma , 1995, Cancer.
[36] Alexander E. Kel,et al. TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..
[37] Lincoln D. Stein,et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.
[38] J. Grosshans,et al. Positive feedback between Dia1, LARG, and RhoA regulates cell morphology and invasion. , 2007, Genes & development.
[39] T. Jacks,et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.
[40] K. Pierce,et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Paul Timpson,et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.
[42] Antonio Rosato,et al. A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.
[43] H. Uramoto,et al. p73 Independent of c-Myc Represses Transcription of Platelet-derived Growth Factor β-Receptor through Interaction with NF-Y* , 2002, The Journal of Biological Chemistry.
[44] D. Kerr,et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] A. Ishisaki,et al. Nuclear factor Y controls the basal transcription activity of the mouse platelet-derived-growth-factor beta-receptor gene. , 1997, European journal of biochemistry.
[46] G. Blandino,et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells , 2014, Oncogene.
[47] E. Petricoin,et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.
[48] A. Fersht,et al. Structural biology of the tumor suppressor p53 and cancer-associated mutants. , 2007, Advances in cancer research.
[49] V. Rotter,et al. Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.
[50] Nadav S. Bar,et al. Landscape of transcription in human cells , 2012, Nature.
[51] C. Prives,et al. A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain , 2001, Molecular and Cellular Biology.
[52] A. Levine,et al. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.
[53] Yujia Dai,et al. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature , 2010, Expert opinion on therapeutic patents.
[54] I. Wistuba,et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs , 2010, Nature.
[55] Christof Fellmann,et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.
[56] Giulia Piaggio,et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.
[57] K. Funa,et al. Isolation and characterization of the mouse PDGF beta-receptor promoter. , 1995, Biochemical and Biophysical Research Communications - BBRC.